Mustang Bio Shareholders’ Equity Growth & History (MBIO)
Mustang Bio's shareholders’ equity was $9.5M for fiscal 2025.
View full Mustang Bio company overviewMustang Bio annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.5M | $13.4M | — |
| 2024 | 2024-12-31 | −$3.9M | −$4.0M | — |
| 2023 | 2023-12-31 | $123,000 | −$46.1M | −99.73% |
| 2022 | 2022-12-31 | $46.3M | −$66.1M | −58.83% |
| 2021 | 2021-12-31 | $112.4M | $14.0M | +14.19% |
| 2020 | 2020-12-31 | $98.4M | $46.8M | +90.57% |
| 2019 | 2019-12-31 | $51.7M | $15.3M | +41.92% |
| 2018 | 2018-12-31 | $36.4M | −$23.4M | −39.17% |
| 2017 | 2017-12-31 | $59.8M | $35.6M | +146.47% |
| 2016 | 2016-12-31 | $24.3M | — | — |
Mustang Bio quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.5M | $4.7M | +160.89% |
| Q1 2026 | 2026-03-31 | $8.6M | $5.0M | +138.18% |
| Q4 2025 | 2025-12-31 | $9.5M | $13.4M | — |
| Q3 2025 | 2025-09-30 | $9.8M | $18.4M | — |
| Q2 2025 | 2025-06-30 | $2.9M | $11.2M | — |
| Q1 2025 | 2025-03-31 | $3.6M | $8.6M | — |
| Q4 2024 | 2024-12-31 | −$3.9M | −$4.0M | — |
| Q3 2024 | 2024-09-30 | −$8.7M | −$12.7M | — |
| Q2 2024 | 2024-06-30 | −$8.3M | −$22.0M | — |
| Q1 2024 | 2024-03-31 | −$4.9M | −$34.8M | — |
| Q4 2023 | 2023-12-31 | $123,000 | −$46.1M | −99.73% |
| Q3 2023 | 2023-09-30 | $4.0M | −$60.3M | −93.77% |
| Q2 2023 | 2023-06-30 | $13.7M | −$68.3M | −83.28% |
| Q1 2023 | 2023-03-31 | $29.8M | −$67.5M | −69.37% |
| Q4 2022 | 2022-12-31 | $46.3M | −$66.1M | −58.83% |
| Q3 2022 | 2022-09-30 | $64.3M | −$57.9M | −47.37% |
| Q2 2022 | 2022-06-30 | $82.0M | −$53.0M | −39.26% |
| Q1 2022 | 2022-03-31 | $97.3M | −$36.0M | −27.02% |
| Q4 2021 | 2021-12-31 | $112.4M | $14.0M | +14.19% |
| Q3 2021 | 2021-09-30 | $122.2M | $45.8M | +59.93% |
| Q2 2021 | 2021-06-30 | $135.0M | $64.0M | +90.10% |
| Q1 2021 | 2021-03-31 | $133.4M | $87.6M | +191.16% |
| Q4 2020 | 2020-12-31 | $98.4M | $46.8M | +90.57% |
| Q3 2020 | 2020-09-30 | $76.4M | $14.0M | +22.37% |
| Q2 2020 | 2020-06-30 | $71.0M | −$415,000 | −0.58% |
| Q1 2020 | 2020-03-31 | $45.8M | $17.3M | +60.84% |
| Q4 2019 | 2019-12-31 | $51.7M | $15.3M | +41.92% |
| Q3 2019 | 2019-09-30 | $62.4M | $17.5M | +38.80% |
| Q2 2019 | 2019-06-30 | $71.4M | $19.8M | +38.44% |
| Q1 2019 | 2019-03-31 | $28.5M | −$27.2M | −48.82% |
| Q4 2018 | 2018-12-31 | $36.4M | −$23.4M | −39.17% |
| Q3 2018 | 2018-09-30 | $45.0M | −$20.1M | −30.88% |
| Q2 2018 | 2018-06-30 | $51.6M | −$17.5M | −25.29% |
| Q1 2018 | 2018-03-31 | $55.6M | −$18.6M | −25.02% |
| Q4 2017 | 2017-12-31 | $59.8M | $35.6M | +146.47% |
| Q3 2017 | 2017-09-30 | $65.1M | $61.8M | +1859.45% |
| Q2 2017 | 2017-06-30 | $69.1M | — | — |
| Q1 2017 | 2017-03-31 | $74.2M | — | — |
| Q4 2016 | 2016-12-31 | $24.3M | $28.4M | — |
| Q3 2016 | 2016-09-30 | $3.3M | — | — |
| As of Dec 31, 2015 | 2015-12-31 | −$4.1M | — | — |
Mustang Bio shareholders’ equity trends
Over the last five fiscal years, Mustang Bio's shareholders’ equity decreased from $98.4M to $9.5M, a change of −$88.9M. The latest reported quarter, Q2 2026, shows $7.5M.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mustang Bio source filings ↗